Actually they want to do development in other countries to gain access to their NHS programs (The purchaser of their product) and then submit that research to our NHS. This works for large Pharma companies that have a global scope but not for small startups that tend to be the most innovative. For them the cost of development is so expensive as to be a barrier to entry. As with all NHS systems it is good for the big companies as it limits competition from the small companies.
Ok, that totally sucks. So yet another move to stifle competition.
Thanks for the explanation :)